Identifying the Right Investigators and Patients for your Study – Mini Podcast Biosimilar Development Capabilities – Watch Now Vaccine Development Capabilities - Brochure Check out our latest Validated PK & ADA Methods List Read about Veeda's partnership with Ahammune Biosciences for first in human studies Check out our Assay List (Method Library)

Brochure / Flyer

img

Molecular Characterization of Biopharmaceuticals

Explore our Physico-chemical Characterization techniques in characterizing biopharmaceuticals for drug development, including proteins, antibodies, vaccines, and nucleic acid-based drugs using High Resolution Mass Spectrometry (HRMS), Liquid Chromatography (LC), Electrophoretic Mobility (EM)

img

Integrated Biosimilar Development Solutions

Offering integrated end-to-end Biosimilar Development Solutions for Peptides, Oligonucleotides, Insulin & Analogs, Fusion Proteins & Recombinant Proteins, mAbs, ADCs

img

Veeda Biopharma's ZipChip Solutions for Advanced Biopharmaceutical Analysis

Explore Veeda Biopharma’s collaboration with Biobeams and 908 devices for offering first-of-its-kind services on the ZipChip platform. ZipChip is a sophisticated platform that enables highly advanced and efficient analysis, specifically designed to cater to the intricate nature of Peptides, Antibodies, Metabolites, and Oligonucleotides.

img

Our Infrastructure for Biopharma Services

Discover how Veeda Biopharma leverages its state-of-the-art infrastructure to accelerate development programs across diverse biopharmaceutical solutions such as Analytics & Characterization, Bioprocess Development, Discovery Biology, and Clinical Bioanalysis.

img

Navigating NCE Development

Explore Veeda's Integrated NCE Clinical Development & Bioanalytical Solutions for global Pharmaceutical and Bio-Pharmaceutical Companies.

img

Olaparib - An Overview of PARP Inhibitors and Clinical Trials

Learn more about Veeda's expertise in designing efficient protocols, optimizing patient recruitment, ensuring regulatory compliance, and maximizing the potential of Olaparib's clinical data. We aim to collaborate with global Pharma and Biopharma companies to accelerate drug development, improve patient outcomes, and shape the future of Oncology.

img

Late Phase Clinical Trial Capabilities

Explore the full range of late-phase clinical trial capabilities, from phase II to phase IV, in the fields of Oncology, Immunology, Respiratory, Hematology, Central nervous system(CNS) and Infectious diseases, delivering groundbreaking insights for novel treatments and enhanced patient outcomes.

img

Phase I Trial Capabilities

Discover our Phase I Trial Capabilities, specializing in first-in-human studies, early-phase clinical trials, and vaccine studies, pioneering the exploration of new medical interventions and paving the way for future advancements in healthcare.

img

Oncology Clinical Trial Capabilities

Discover our comprehensive Oncology Clinical Trial Capabilities, dedicated to advancing the field of cancer research through cutting-edge studies focused on Breast Cancer, Prostate Cancer, Ovarian Cancer, Multiple Myeloma, and Small Cell Lung Cancer, offering hope and innovative treatments for patients worldwide.

img

Infectious Diseases Drug-development Solutions

Experience a transformative approach to Infectious Disease Drug-development Solutions, integrating ELISPOT studies, COVID-19 research, Polio vaccine studies, and pioneering investigations into blood and skin infections, driving the discovery of innovative treatments to combat complex infectious diseases and promoting global well-being.

img

Veeda Group - Integrated Drug-development Services

Veeda provides a comprehensive range of services covering pre-clinical studies, Phase I to Phase IV clinical trials, bioavailability and bioequivalence studies, as well as bioanalytical services for both small and large molecules. With a commitment to scientific excellence and regulatory compliance, we deliver reliable data and insights to drive successful drug development.

img

Streamlining Biotherapeutic Development: Analytics and Characterization Solutions

Preferred solution partner for physico-chemical, structural characterization and analytical CMC support for broad range of biotherapeutics ranging from peptides, oligos, recombinant-conjugated-fusion protein, monoclonal antibodies (mAbs), bispecific, antibody (Ab) fragments, antibody-drug conjugates to biopolymers.

img

Accelerating Biopharma Development: Customized Clinical Bioanalysis Solutions

Offering services to perform Pharmacokinetics, Pharmacodynamics, immunogenicity testing, vaccine sciences and biomarker assays for the development of biotherapeutics with Good Clinical Laboratory Practice (GCLP) compliance.

img

Biotherapeutic Process Development Solutions

The process development at Biopharma Division of Veeda is equipped for expression and purification of heterologous proteins in microbial and mammalian cells (CHO; HEK) for therapeutic and non-therapeutic proteins with process development and scale-up at 2 L and 5 L bioreactors.

img

Biopharma Solutions: Discovery Biology

Discovery Biology at Veeda Biopharma division, with its Assay Biology and ADMET/ DMPK solutions offers a large suite of In vitro assays to support your stand-alone research needs or integrated solutions.

img

Integrated Solutions for Generic & Novel GLP-1 Receptor Agonists: Spanning Preclinical to Clinical Development

Veeda offers integrated solutions for the development of innovative and generic GLP-1 (Glucagon-Like Peptide-1) receptor agonists, covering all stages from meticulous preclinical assessments to advanced clinical trials.

img

Enhancing Chiral Bioanalysis with Supercritical Fluid Chromatography for NCE molecules

Dr. Abhishek Gandhi, Mr. Jayrajsinh Chudasama, Mr. Kishor Gohil, Dr. Tulsidas Mishra, Ms. Swati Guttikar, Rahmanzadeh Gholamreza, Winter Serge
Event: EBF 2023
Location: Barcelona

img

Method Development & Validation for Ferric Carboxymaltose Formulation

A Novel Approach for Quantitation of Total Iron and Transferrin Bound Iron in Human serum samples by using ICP-OES
Dr. Pritesh Contractor, Dr. Shanti S Yadav, Dr. Ajay Gupta. Ms. Swati Guttikar, Dr. E. Venu Madhav
Event: APA-2020
Location: Ahmedabad

img

Method Development & Validation of ISDN and its Metabolites

Sensitive, Reproducible & Simultaneous Bioanalytical method of ISDN and its Metabolites in Human Matrix samples for PK Analysis
Ms. Swati Guttikar, Mr. Jayrajsinh Chudasama, Mr. Vipul Chauhan
Event: WRIB 2023
Location : United States

Request for Proposal

Submit your details and we’ll be in touch shortly. You can also email us if you would prefer.